Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 4/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | USP14 | P54578 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL550162 | 1.00 | SLC6A9 (0.38) | SLC6A9HSD11B1HCRTR1HCRTR2KDM4E | |
| SCHEMBL549286 | 0.92 | HSD11B1 (0.45) | SLC6A9HSD11B1HCRTR1HCRTR2KDM4E | |
| SCHEMBL4722964 | 0.91 | ALDH1A1 (0.40) | SLC6A9HSD11B1HCRTR1HCRTR2KDM4E | |
| SCHEMBL4829848 | 0.91 | ALDH1A1 (0.40) | SLC6A9HSD11B1HCRTR1HCRTR2KDM4E | |
| SCHEMBL4718438 | 0.91 | ALDH1A1 (0.40) | SLC6A9HSD11B1HCRTR1HCRTR2KDM4E | |
| SCHEMBL550885 | 0.89 | SLC6A9 (0.39) | SLC6A9HSD11B1HCRTR1HCRTR2KDM4E | |
| SCHEMBL2701263 | 0.89 | SLC6A9 (0.39) | SLC6A9HSD11B1HCRTR1HCRTR2KDM4E | |
| SCHEMBL550672 | 0.88 | HSD11B1 (0.38) | HSD11B1HCRTR1HCRTR2KDM4EALDH1A1 | |
| SCHEMBL2697999 | 0.88 | HSD11B1 (0.38) | HSD11B1HCRTR1HCRTR2KDM4EALDH1A1 | |
| SCHEMBL550174 | 0.88 | HSD11B1 (0.38) | HSD11B1HCRTR1HCRTR2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812005-B1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-09-16 | — | — | EP | claimed |
| US-8563570-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | claimed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | claimed |
| EP-2450351-A1 | Lactam compounds and their use as pharmaceuticals | Incyte Corporation (US) | 2012-05-09 | — | — | EP | claimed |
| US-8110581-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-02-07 | — | — | US | claimed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | claimed |
| EP-1812005-A2 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-08-01 | — | — | EP | claimed |
| WO-2006053024-A2 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-05-18 | — | — | WO | claimed |
| EP-2173750-B9 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | INCYTE CORP (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-1812005-B1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-1812005-B1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2918586-A1 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | Incyte Corporation (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2540723-B1 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | INCYTE CORP (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8563570-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| EP-2173750-A1 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | Incyte Corporation (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2008157752-A1 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | INCYTE CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116382-A1 | Lactam compounds and their use as pharmaceuticals | HSD11B1, HSD11B2, HSD17B1 | SLC6A9 2337/4885HSD11B1 1/4885HCRTR1 2917/4885 |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | SLC6A9 2337/4885HSD11B1 1/4885HCRTR1 2917/4885 |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | SLC6A9 2337/4885HSD11B1 1/4885HCRTR1 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.